BON Launches AI-Powered New Drug Research and Development

Rhea-AI Summary

Bon Natural Life (Nasdaq: BON) has announced the launch of its AI-powered drug research and development business, marking a strategic expansion in its pharmaceutical operations. The company will leverage its extensive Traditional Chinese Medicine (TCM) compound library combined with artificial intelligence to accelerate drug discovery.

With nearly 20 years of experience in natural product research, BON aims to enhance its drug discovery process through AI-driven models that will analyze and identify promising lead compounds. CEO Yongwei Hu expressed optimism about achieving breakthroughs in drug discovery by combining their TCM-derived compound libraries with AI screening technology.

Positive

• Integration of AI technology expected to improve efficiency and success rate of drug discovery
• Leverages existing library of natural compounds with proven therapeutic value
• Strategic expansion into pharmaceutical R&D utilizing proprietary TCM compounds

Negative

• Previous R&D efforts were limited by traditional screening technologies
• Early-stage initiative with no immediate revenue impact
• No specific timeline or metrics provided for expected results

XI'AN, China, July 30, 2025 /PRNewswire/ -- Bon Natural Life Limited (Nasdaq: BON) ("BON" or "the Company"), a leading provider of bio-ingredient solutions for the natural health and personal care industries, today announced the official launch of its AI-driven drug research and development (R&D) business. Leveraging its extensive library of natural compounds - many derived from Traditional Chinese Medicine (TCM) - the Company will apply artificial intelligence algorithms to identify high potential lead compounds, marking a significant evolution in its pharmaceutical strategy.

A lead compound is a molecule with specific biological activity and a chemical structure that serves as a foundation for further development in drug discovery. Identifying such compounds through activity screening is a fundamental step in early-stage pharmaceutical R&D.

With nearly two decades of experience in the research and development of natural products, BON has curated a robust library of biologically active compounds — many with proven therapeutic value and high druggability. While previous R&D efforts were limited by traditional screening technologies, the integration of advanced AI-driven models is expected to significantly enhance the efficiency, speed, and success rate of BON's drug discovery process.

Yongwei Hu, BON's CEO, stated, "Backed by the high druggability of our TCM-derived compound libraries and the efficiency of AI-powered screening technology, we are optimistic about Bon's potential to achieve meaningful breakthroughs in drug discovery. This initiative represents a strategic leap forward for our company and reinforces our long-term commitment to innovation in pharmaceutical research."

The Company's new AI-driven platform is designed to quickly analyze and identify promising lead compounds for further optimization, supporting BON's broader goals of accelerating the development of innovative therapies rooted in natural product chemistry.

About Bon Natural Life Limited ("BON")

BON is a Cayman Islands company engaged in the business of natural, health, and personal care industries. For more information, please visit http://www.bnlus.com.

Safe Harbor Statement

This press release contains certain statements that may include "forward-looking statements." All statements other than statements of historical fact included herein are "forward-looking statements." These forward-looking statements are often identified by the use of forward-looking terminology such as "believes,""expects" or similar expressions, involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, they do involve assumptions, risks, and uncertainties, and these expectations may prove to be incorrect. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company's periodic reports that are filed with the Securities and Exchange Commission and available on its website (http://www.sec.gov). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.

View original content:https://www.prnewswire.com/news-releases/bon-launches-ai-powered-new-drug-research-and-development-302517073.html

SOURCE Bon Natural Life Limited

FAQ

What is BON's new AI-powered drug research initiative?

BON is launching an AI-driven drug research platform that will analyze their Traditional Chinese Medicine compound library to identify promising lead compounds for drug development.

How will AI technology benefit BON's drug discovery process?

AI technology is expected to significantly enhance the efficiency, speed, and success rate of BON's drug discovery process compared to traditional screening methods.

What experience does BON have in natural product research?

BON has nearly 20 years of experience in natural product research and development, maintaining a robust library of biologically active compounds with therapeutic value.

Who is leading BON's AI drug discovery initiative?

The initiative is being led by BON's CEO Yongwei Hu, who expressed optimism about achieving breakthroughs by combining TCM-derived compounds with AI screening technology.

What is BON's competitive advantage in AI drug discovery?

BON's competitive advantage lies in its extensive library of TCM-derived compounds with proven therapeutic value and high druggability, combined with new AI screening capabilities.